Sale of Assets
Celliance has acquired gene expression technology for an undisclosed sum from a UK product development company...
Celliance has acquired gene expression technology for an undisclosed sum from a UK product development company. The ubiquitous chromatin opening element (UCOE) technology was deemed as non-core to Innovata after a strategic review by its new management team earlier this year.
UCOEs are said to improve the yield, consistency and stability of protein production in cultured mammalian cells, which allows simpler and quicker generation of proteins at small-scale for R&D. There is also the capacity for larger-scale manufacture of protein therapeutics, using stable, highly productive cell-lines, which are easily isolated with the technology.
The technology is under license to several pharmaceutical companies in North America, Europe and Japan. The separation from UCOEs is a move by the UK based company to refocus attention to respiratory disease and inhaled therapies. The assets that will be transferred to Celliance have no book value.
For more information about Celliance Corporation, please visit the website at
http://www.celliancecorp.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
